Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

Person › Details

Ugur Sahin (BioNTech AG)

Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)

	Organisation	BioNTech AG
	Today	BioNTech SE (Nasdaq: BNTX)
	Group	BioNTech (Group)
	Former/major organisation	Ribological GmbH
	Today	BioNTech RNA Pharmaceuticals GmbH
	Group	BioNTech (Group)
	Product	drug discovery
	Product 2	cancer drug
	Source	4SC AG. (7/17/12). "Press Release: 4SC Discovery, Crelux and Ribological Launch Collaboration for the Discovery and Optimisation of New Anti-cancer Drugs [no US". Planegg-Martinsried.

Record changed: 2020-11-12

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Ugur Sahin

[1] BioNTech SE. (11/11/20). "Press Release: Pfizer and BioNTech Reach an Agreement to Supply the EU with 200 Million Doses of Their BNT162b2 mRNA-based Vaccine Candidate against COVID-19". New York, NY & Mainz....
[2] BioNTech SE. (11/9/20). "Press Release: Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study". New York, NY & Mainz....
[3] BioNTech SE. (10/6/20). "Press Release: BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2". New York, NY & Mainz....
[4] BioNTech SE. (9/15/20). "Press Release: BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine Program BNT162". Mainz....
[5] BioNTech SE. (7/31/20). "Press Release: BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo (cemiplimab) Combination in Melanoma". Mainz....
[6] BioNTech SE. (7/31/20). "Press Release: Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate". New York, NY & Mainz....
[7] BioNTech SE. (7/27/20). "Press Release: Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study". New York, NY & Mainz....
[8] BioNTech SE. (7/22/20). "Press Release: Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2". New York, NY & Mainz....
[9] BioNTech SE. (7/20/20). "Press Release: Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2". New York, NY & Mainz....
[10] BioNTech SE. (7/1/20). "Press Release: Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2". New York, NY & Mainz....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]